Immune cell therapy trial offers new hope for young hodgkin lymphoma patients
NCT ID NCT07575893
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new treatment for children, adolescents, and young adults with a certain type of Hodgkin lymphoma that has come back after initial therapy. The treatment uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells. The main goal is to find the safest and most effective dose of these modified cells.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial